31 Jan 2018 10:39
31 January 2018 |
Futura Medical plc
("Futura" or "the Company")
Total Voting Rights
Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology announces that, for the purposes of the FCA's Disclosure Guidance and Transparency Rules, the Company's total issued share capital at the date of this announcement is 120,856,002 Ordinary Shares.
Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is 120,856,002 and this figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information please contact: For media enquiries please contact:
Futura Medical plc Buchanan Communications Limited |
James Barder, Chief Executive Mark Court / Stephanie Watson / + 44 (0) 1483 685 670 Sophie Wills james.barder@futuramedical.com + 44 (0) 20 7466 5000 www.futuramedical.com |
Nominated AdviserN+1 SingerAubrey Powell / Liz Yong / Jens Ehrenberg+44 (0) 20 7496 3000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
Futura Medical (FUM)